L., Galstyan, A., Holler, E
Unfortunately, this trial did not pass Phase I with five of the seven enrolled patients experiencing serious adverse effects, including supraventricular tachycardia, convulsion, and pulmonary embolism
For laboratories focused on oral peptide pharmacology, these capsules eliminate the reconstitution step and associated sterility concerns inherent in working with lyophilized powders
Monitoring recommendations Researchers using cagrilintide should consider regular monitoring including: Blood work every 3 to 6 months including metabolic panel, lipid panel, liver function, and pancreatic enzymes Thyroid function tests at baseline and periodically Body composition assessment to track lean mass versus fat mass changes Heart rate monitoring particularly during titration Nutritional status markers including vitamin B12, iron, and vitamin D The peptide research and studies section provides broader context for evaluating emerging safety data as it becomes available
Together, our findings support that TGF 1 is driving BBB permeability via downregulation of claudin-5 and upregulation of MMP9 and that these effects are dependent on SMAD3
About the study The phase 3a, multicenter, randomized, double-blind, placebo- and active-controlled REDEFINE 1 trial enrolled 3,417 adults across 22 countries